If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Change of Auditor

27 Sep 2017 17:32

RNS Number : 0214S
Premier Veterinary Group PLC
27 September 2017
 

PREMIER VETERINARY GROUP PLC

("PVG", the "Company" or the "Group")

 

Change of Auditor

 

 

London, UK, 27 September 2017 - Premier Veterinary Group plc (LSE: PVG) announces that following a tender process led by the Audit Committee, the Board of Premier Veterinary Group PLC has approved the proposed appointment of PricewaterhouseCoopers LLP as the Company's auditor for the financial year ending 30 September 2017.

 

The Company has reached mutual agreement with its present auditors, Grant Thornton UK LLP ("Grant Thornton"), that with effect from the 20 September 2017, Grant Thornton should no longer act as the Company's auditor.

 

Grant Thornton's corporate finance team were engaged as lead advisor in August 2016 to support the potential disposal negotiations of the Premier Buying Group division. In light of the Revised Ethical Standard issued by the Financial Reporting Council and the FRC's subsequent Staff Guidance Notes, the Company's Audit Committee and Grant Thornton have agreed that Grant Thornton's independence could be impaired by their provision of certain non-audit services.

 

The Company and Grant Thornton have therefore mutually agreed that auditor independence is best safeguarded by Grant Thornton's resignation as auditor of the Company.

 

As required by section 519 of the Companies Act 2006 (the "Act"), Grant Thornton has deposited a statement with the Company of the circumstances connected with it ceasing to hold office as auditor of the Company. In accordance with the requirements of section 520 of the Act, a copy of the statement received from Grant Thornton will be sent to all shareholders.

 

The Company would like to thank Grant Thornton for its service to the Company.

 

 

For further information, please contact:

 

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Will Evans, Chief Financial Officer

 

Note to Editors:

 

PVG's services to third party veterinary practices, through its wholly-owned subsidiary, Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare programme for pets branded "Premier Pet Care Plan" ("PPCP"). In the US, where veterinary practices are known as veterinary hospitals, PPCP is marketed through the Company's wholly owned subsidiary, Premier Vet Alliance (US) Limited.

 

PPCP is a structured, preventative healthcare programme for cats, dogs and rabbits and is available only through veterinary practices/hospitals. The programme is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

 

PPCP uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed more quickly and not 

given a chance to advance. What truly sets PPCP apart is its unique approach of offering an end-to-end solution and support to the practice/hospital, which has been proven to work extremely well. PVA works alongside practices/hospitals to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice/hospital performance.

 

For further details:

 

http://www.premiervetgroup.co.uk/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQDLFLDKFXBBF
Date   Source Headline
22nd Apr 20093:34 pmRNSAGM Results
7th Apr 200911:09 amRNSAnnual Information Update
7th Apr 20097:00 amRNSResearch Update
17th Mar 20095:03 pmRNSHolding(s) in Company
13th Mar 20094:25 pmRNSHolding(s) in Company
11th Mar 20097:00 amRNSFinal Results
2nd Mar 200911:21 amRNSVoting Rights and Capital
26th Feb 20097:00 amRNSPatent Filing
17th Feb 20092:14 pmRNSHolding(s) in Company
16th Feb 20095:39 pmRNSHolding(s) in Company
16th Feb 20097:00 amRNSResearch Update
5th Feb 200910:50 amRNSDealing by Employee Benefit Trust
2nd Feb 20097:00 amRNSDirector/PDMR Shareholding
21st Jan 20094:40 pmRNSSecond Price Monitoring Extn
21st Jan 20094:37 pmRNSPrice Monitoring Extension
21st Jan 200912:12 pmRNSNotice of Results
14th Jan 20097:00 amRNSRe Agreement
9th Jan 200910:23 amRNSHolding(s) in Company
8th Jan 20097:00 amRNSTrinam Phase III trial to commence
6th Jan 20097:00 amRNSResearch Update
31st Dec 20089:00 amRNSTotal Voting Rights
16th Dec 20083:46 pmRNSNotification of Major Interests in Shares
9th Dec 20084:40 pmRNSSecond Price Monitoring Extn
9th Dec 20084:35 pmRNSPrice Monitoring Extension
9th Dec 20087:00 amRNSRegulatory Approval
5th Dec 20082:28 pmRNSBlocklisting Six Monthly Return
1st Dec 20087:00 amRNSRegulatory Application
24th Nov 200811:58 amRNSDirector/PDMR Shareholding
13th Nov 20087:00 amRNSInterim Management Statement
20th Oct 20087:00 amRNSProduct Launch
2nd Oct 20087:00 amRNSArk secures reimbursement for Neuropad
30th Sep 20085:06 pmRNSVoting Rights and Capital
17th Sep 20081:08 pmRNSHolding(s) in Company
27th Aug 20087:00 amRNSInterim Results
27th Aug 20087:00 amRNSResearch Update
26th Aug 20084:08 pmRNSHolding(s) in Company
1st Aug 200810:47 amRNSVoting Rights and Captial
31st Jul 20081:12 pmRNSHolding(s) in Company
30th Jul 20087:00 amRNSResearch Update
16th Jul 20087:00 amRNSResearch Update
8th Jul 200811:00 amRNSArk opens new manufacturing f
24th Jun 200811:28 amRNSHolding(s) in Company
18th Jun 20087:00 amRNSResearch Update
6th Jun 200812:10 pmRNSBlocklisting Application
3rd Jun 200810:58 amRNSBlocklisting Interim Review
3rd Jun 200810:51 amRNSBlocklisting Interim Review
2nd Jun 20087:00 amRNSRegulatory Approval
30th May 20084:52 pmRNSVoting Rights and Capital
30th May 20087:00 amRNSResearch Update
22nd May 20081:27 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.